Use of bisphenolic compounds to treat type ii diabetes

Abstract

This invention is directed to methods for treatment of non-insulin-dependent diabetes mellitus, for reducing blood glucose levels, or hyperglycemia. The methods entail administering to a mammal in need of such treatment a therapeutically effective amount of a composition whose active ingredient consists essentially of a compound of the following structure or a pharmaceutically acceptable salt thereof: ##STR1## In the compound R and R' are independently H or a C.sub.1 -C.sub.20 alkyl or C.sub.2 -C.sub.20 alkenyl group which may be substituted or unsubstituted. Alternatively, R and R' are such that together a cycloalkyl or cycloalkenyl ring is formed. In the chain linking the two phenolic derivatives each of (C(R).dbd.C(R')) or (C(R)(R')) are the same or different. A and A' are independently C.sub.2 -C.sub.20 acylamino, C.sub.2 -C.sub.20 acyloxy, C.sub.2 -C.sub.20 alkanoyl, C.sub.2 -C.sub.20 alkoxycarbonyl, C.sub.1 -C.sub.20 alkoxyl, C.sub.1 -C.sub.20 alkyl amino, C.sub.2 -C.sub.20 alkyl carboxyl, amino, C.sub.2 -C.sub.20 carbalkoxyl, carboxyl, cyano, halo, hydroxy. B and B' are independently H, C.sub.2 -C.sub.20 alkanoyl, C.sub.3 -C.sub.20 alkenoyl, C.sub.2 -C.sub.20 alkenyl, C.sub.2 -C.sub.20 alkoxycarbonyl, C.sub.1 -C.sub.20 alkyl, aroyl, aralkanoyl, C.sub.2 -C.sub.20 carbamoyl, or phosphate. The invention is also directed to methods of treatment using a bisphenolic compound in conjunction with another hypoglycemic or hypolipidemic agent.